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Presence of D4 dopamine receptors in human
prefrontal cortex: a postmortem study
Presença de receptores dopaminérgicos D4 em
córtex cerebral humano: um estudo post-mortem
Abst rac t
Objective: The aim of our study was to explore the presence and the distribution of D4 dopamine receptors in postmortem
human prefrontal cortex, by means of the binding of [3H]YM-09151-2, an antagonist that has equal affinity for D2, D3 and D4
receptors. It was therefore necessary to devise a unique assay method in order to distinguish and detect the D4 component.
Method: Frontal cortex samples were harvested postmortem, during autopsy sessions, from 5 subjects. In the first assay, tissue
homogenates were incubated with increasing concentrations of [3H]YM-09151-2, whereas L-745870, which has a high affinity for
D4 and a low affinity for D2/D3 receptors, was used as the displacer. In the second assay, raclopride, which has a high affinity for
D2/D3 receptors and a low affinity for D4 receptors, was used to block D2/D3. The L-745870 (500 nM) was added to both assays
in order to determine the nonspecific binding. Results: Our experiments revealed the presence of specific and saturable binding
of [3H]YM-09151-2. The blockade of D2 and D3 receptors with raclopride ensured that the D4 receptors were labeled. The mean
maximum binding capacity was 88 ± 25 fmol/mg protein, and the dissociation constant was 0.8 ± 0.4 nM. Discussion and
conclusions: Our findings, although not conclusive, suggest that the density of D4 receptors is low in the human prefrontal
cortex.
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Resumo
Objetivo: O objetivo deste estudo foi quantificar a presença e a distribuição de receptores dopaminérgicos do tipo 4 (D4) no
córtex cerebral humano em amostras post-mortem através do bloqueio com 3H-YM-09151-2 – um antagonista com afinidade
equivalente pelos receptores D2, D3 e D4 – e do desenvolvimento de um método para a detecção específica do componente D4.
Método: Foram obtidas amostras de córtex cerebral de cinco cadáveres. Em um primeiro ensaio, os homogeneizados de tecido
cerebral foram incubados em concentrações crescentes de 3H-YM-09151-2, enquanto que o L-745,870, ligante que apresenta
grande afinidade pelo receptor D4 e baixa afinidade por D2 e D3, foi utilizado como controle. Em um segundo ensaio, a
racloprida, que apresenta alta afinidade por receptores D2 e D3, mas baixa afinidade por D4, foi usada para bloquear D2 e D3.
O L-745,870 foi adicionado em ambos os ensaios para determinar o bloqueio não específico. Resultados: Os resultados do
experimento demonstraram a presença de um bloqueio específico e saturável com 3H-YM-09151-2. O bloqueio de receptores D2
e D3 com racloprida confirmou que apenas os receptores D4 livres foram avaliados. A Bmax (média ± DP) foi de 88 ± 25 fmol/mg
de proteínas, enquanto que a Kd (média ± DP) foi de 0,8 ± 0,4 nM. Discussão e conclusões: Tais achados, ainda que não
definitivamente conclusivos, sugerem a presença de uma baixa densidade de receptores D4 no córtex pré-frontal humano.
Descritores: Dopamina; Receptores dopaminérgicos; Receptores dopaminérgicos do tipo D4; Cérebro; Córtex pré-frontal
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Int roduct ion
The synthesis of the so-called ‘atypical’ antipsychotics, in
particular that of clozapine, represented a fundamental
advance in the management of psychotic disorders and
promoted new research s t ra teg ies  to  exp lore the i r
pathophysiology.1 All atypical antipsychotics are characterized
by the blockade of dopamine receptors, especially in the
mesolimbic and mesocortical pathways, coupled with specific
antagonism of serotonin type 2 (5-HT2) receptors and diverse
effects on various other receptors.2-5
Dopamine receptors are currently classified in five subtypes
that are grouped in two main families: the D1 family, which
includes the D1 and D5 receptors; and the D2 family, which
includes the D2, D3 and D4 receptors.6 Clozapine has a 20-
times higher binding affinity for D4 receptors than for the other
dopamine receptors. Therefore, this receptor subtype seems
to be relevant to the mechanism of action of clozapine and,
perhaps to a larger extent,  to that of  a l l  atypical
antipsychotics.2,7 The D4 receptors, like all of those belonging
to the D2 family, have a high affinity for dopamine, as well as
for adrenaline and noradrenaline, and inhibit adenylate-cyclase
activity. Since there is no selective ligand capable of labeling
D4 receptors, there is little information available on their
distribution in the human brain. Although the different
techniques employed, such as the methods used for binding
subtraction, autoradiography and determination of mRNA
expression, make it difficult to draw direct comparisons among
studies, D4 receptors seem to be mainly distributed in the fron-
tal cortex, limbic areas (such as the amygdala and hippocampus)
and the mesencephalon, as well as (at a very low density) in
the basal ganglia and olfactory tubercle. Nevertheless, the
distribution of D4 receptors appears to be meager and quite
unique in comparison with that of the other dopamine receptors,
which are mainly found in striatal areas.8-10
The aim of our study was, therefore, to explore the presence
and distribution of D4 receptor in postmortem human prefrontal
cortex by means of the direct binding of [3H]YM-09151-2.
Since this radioligand is an antagonist that has equal affinity
for D2, D3 and D4 receptors, it was therefore necessary to
devise a specific experimental assay in order to selectively
distinguish and detect the D4 component. The prefrontal cortex
was chosen because it has been reported to be involved in the
so called ‘negative symptoms’ of psychoses, for which clozapine
is particularly effective.
Method
1. Subjects
Prefrontal cortex samples were taken postmortem, during
autopsy sessions, from five subjects (three male and two female;
mean age at time of death: 62 ± 4 years). The samples were
immediately packed in dry ice and stored in a -80° freezer.
Autolysis time (i.e., the time between death and the freezing of
the samples) ranged from 7 h to 25 h. All subjects had died
from causes not primarily involving the brain (2 from myocardial
infarction, 2 from pulmonary embolism and 1 from respiratory
failure) and had not suffered from any psychiatric or neurological
disorders. Nor had any received psychotropic drugs, according
to their medical charts. The study was approved by the Ethics
Committee of the University of Pisa, in Pisa, Italy.
2. Preparation of prefrontal cortex homogenate
The prefrontal cortex were defrosted and separated from the
white matter. In order to achieve the original 4 mg/ml wet
weight, the tissue was re-suspended in D4 buffer (120 mM
NaCl, 1.5 mM CaCl
2
, 4 mM MgCl
2
, EDTA 1 mM, pH 7.4)
according to the method described by Seeman et al.11-12 The
tissue was then homogenized in an Ultra-Turrax homogenizer
(IKA Labor technik, Staufen, Germany) in D4 buffer. The
homogenate was not washed and centrifuged, since these
procedures can result in the loss of 15 to 60% of the receptors.
3. Binding of [3H]YM-09151-2
The radioligand employed has an affinity for D2, D3 and D4
receptors. Therefore, in order to determine the effective D4
component labeling for each sample, two separate binding
assays were performed, each involving more than one ligand.
In the first assay, 500 μl of cor tex homogenate were
incubated with six increasing concentrations of [3H]YM-09151-
2 (specific activity, 85.5 Ci/mmol; NEN, Milan, Italy) ranging
from 0.015 nM to 2.6 nM, in a final volume of 1.5 ml. The
D4 receptor density was determined by calculating the
difference between the [3H]YM-09151-2 total binding (Figure
1A) and the binding obtained using a ligand that has a high
affinity for D4 (Kd = 0.4 nM) and a low affinity for D2/D3
receptors (Kd = 0.9 μM and 2.3 μM for D2 and D3 receptors,
respectively),12 namely L-745870 (Sigma-Aldrich, Milan, Italy)
at 500 nM (Figure 1B).
In the second assay, total binding was determined using the
same concentrations of [3H]YM-09151-2 described above, and
selective D4 binding was estimated in the presence of 100
nM raclopride (Sigma-Aldrich), which has high affinity for
D2/D3 receptors and low affinity for D4 receptors (Figure 1C).
The L-745870 (500 nM) was used to determine the nonspecific
binding (Figure 1D). All samples were assayed in triplicate.
The incubation with [3H]YM-09151-2 was performed for 2
h at 22°C. The bound ligand was separated from the free
ligand by vacuum filtration through GF/C fiber filters (Whatman,
Maidstone, UK), which were pre-soaked in polyethyleneimine
(2%) to minimize nonspecific binding to the filters. Radioactivity
was counted by a liquid scintillation counter (LS-1600,
Beckman, Fullerton, CA, USA).
Using this procedure, we expected to obtain, for each
subject, two comparable values that would correspond to D4
receptor density.
The equilibrium-saturation binding parameters, i.e., the
maximum binding capacity (Bmax, expressed in fmol/mg
protein) and the dissociation constant (Kd, expressed in nM),
were analyzed using the EBDA i terat ive curve- f i t t ing
computer program.13
4. Statistical analysis
The differences between the two groups of binding parameter
values obtained in the two assays were analyzed by conducting
Student’s t-tests (paired, two-tailed) using the computer
program Statview V for Macintosh.
Resu l t s
We identified specific and saturable binding for the D2/D3/
D4 receptor antagonist [3H]YM-09151-2 in postmortem human
prefrontal cortex. Figure 2 shows the representative saturation
curve and Scatchard plot obtained in the second assay from
subject no. 5 (a 63-year-old male).
The overall mean Bmax and Kd values obtained in the two
assays were 88 ± 25 fmol/mg protein and 0.8 ± 0.4 nM,
respectively. The mean Bmax and Kd values obtained in the
first assay were 90 ± 30 fmol/mg protein and 0.8 ± 0.4 nM,
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respectively. The mean Bmax and Kd values obtained from the
second assay were 86 ± 23 fmol/mg protein and 0.8 ± 0.4 nM,
respectively. There were no significant differences between the
two groups of assays regarding Bmax or Kd (p > 0.05). The
Bmax and Kd values for each subject are reported in Table 1.
The blockade of D2 and D3 receptors with raclopride ensured
that the D4 receptors were labeled.
Discussion and conclusions
The main finding of the present study is that D4 receptors were
identified in postmortem human prefrontal cortex using direct
binding techniques. The majority of the data available previously
was obtained from studies performed in the rat or human brain
with ligands such as [3H]nemonapride, [3H]YM-09151-2 or
[3H]raclopride.11-12,14 The authors of such studies typically
extrapolated the presence of D4 receptors by using subtraction
methods. The ensuing findings revealed that D4 receptors were
essentially distributed in various limbic areas, in the cerebral
cortex and (perhaps) in cortical pyramidal cells, as well as,
to a lesser extent, in the basal ganglia, probably on GABAergic
neurons.15 By means of radioactive probes, such as specific
messenger RNAs, D4 receptors have been labeled, mainly
in the nucleus accumbens, cerebral cortex and basal
ganglia:8-9 This is consistent with the results of quantitative
analyses of autoradiographs, which also revealed that the
density of D4 receptors is low in comparison to that the
other subtypes.16 Only one group of authors studied human
and rat brains and identified D4 receptors in both.10 The
authors used [3H]NGD 94-1, a selective D4 antagonist, and
described some differences between the two species,
especially in terms of affinity. However, the density of the
sites labeled in the prefrontal cortex in the present study was
8-times higher than that reported by those authors.10
The principal limitation of our study is that, due to the lack
of sufficient tissues, we could not perform a complete analysis
of various brain areas. For the same reason, we could not
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carry out the pharmacological characterization of the binding,
which is considered essential. Therefore, we cannot even suggest
an explanation for the fact that the Kd values obtained were
considerably higher than those reported in the literature.
The characteristic distribution of D4 receptors in the human
brain, coupled with the observation that clozapine, the first
atypical antipsychotic introduced into clinical practice, has a
high affinity for these receptors (approximately 20-times higher
than its affinity for the other dopamine receptors),2 suggests
that D4 receptors are involved in at least some symptoms of
schizophrenia and psychosis. Following this line of thought,
various authors have reported alterations in the D4 receptors
in the frontal cortex of schizophrenic patients, although these
reports are questionable in terms of the previously mentioned
methodological limitations, as well as because the patients
involved had been t reated for several  years with
antipsychotics.17-20 It has been also proposed that the
polymorphic variants of D4 receptors are responsible for the
heterogeneous patient response to clozapine, as evidenced by
the fact that a segment of the population is resistant to clozapine.
However, none of the genetic studies conducted to date have
demonstrated any correlation between polymorphism of the
D4 receptor gene and the response to clozapine.21-22
Further studies are necessary in order to draw a comprehensive
map of D4 receptors in the human brain and to clarify their
roles in the physiology of the central nervous system, as well as
in the pathophysiology of neuropsychiatric disorders.
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